<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 305 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page304.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=305">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 305 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 305</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=305"><img src="../thumb/305.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>268 / 2020-04                                                            Anti-Microbials - 18.12
   Indications: Combin.ther.with other anti-retrovir. for HIV infect.in   HIV-infect.managem., when discont./ dos.reduct.of one of the act.  cept. in combinat.with other methods, methadone withdr., per.monit.
   adults, childr.& mothers not breast feed.  subst.indicat. admin. relev.separ.prep., elderly, not recomm.in creat.   anticonvuls.plasma lev., teratogen., women of child-bear.potent.to
   (S4) ORAL SOL, [P/S] A40/20.2.8/0562. 50 mg/5 ml  clear. less than 50 ml/min., mild.hepat. impairm., addit.inform.relat.  undergo pregn.test.bef.init. ther., poss.pass.into breast milk, discont.
   710634-001: 240 ml, R126,39  to use of lamuvidine in hepatit. B infect.treatm.in prod.lit.if used con-  in sev.liv. impairm., not a cure, developm.of opportunist.infects.&
   Dosage: In combinat.with other antiretrovir: Adults: 500 or 600 mg/  com. for HBV/HIV ther., incr.risk of sev./potent.fatal hepat. adverse   other HIV complicat. poss.contin., ther.not prov.to reduc. transmiss.
   day in 2-3 div.dos. Dos.of &gt;1 000 mg/day in div.dos.has been used.   react.in chron.hepatit. B/C pts.with treat. with combin.anti-retrovir.,   risk, ref.to prod.lit.when prescrib.other meds., consid.simultan.dis-
   Effectiven. of &lt;1000 mg dly.in treatm./prev.of HIV assoc. neurologic.  per.monit. recomm. if Dumiva discont.in pts.co-infect.with hepat. B   cont.of all antiretrovir. meds.if combinat.regim.is interrupt.because
   dysfunct.unknown.            virus as lamivudine withdr.poss.result in ac. hepatit. exacerbat.,   of suspect.intol.& restart medicat.at same time upon resolut.of in-
   Childr: 3 mnths-12 yrs: In combinat.with other antiretrovir: 360-  pre-exist.liv.dysfunct. incl. chron. act.hepatit., interr./discont.ther.in   tol.sympts., intermitt.monother./ sequent. reintroduct.not advis., dis-
       2
   480 mg/m /day in 3-4 div.dos. Max. dos.not to exceed 200 mg every   case of worsen.liv dis., pt.monit.with concom.co-trimoxazole, poss.  cont.in sev. rash, consid.prophylax.with appropr.anthistam.in childr.,
   6 hrs. Effectiven.of &lt;720 mg/m  dly. (i.e.180 mg/m 6 hrly) in treatm./  methadone withdr.sympt.with concom. abacavir, avoid pneumocystis   antihistam./corticoster.for mild to mod.rash to improv.tol.& resolv.
                       2
               2
   prev.of HIV assoc. neurologic.dysfunct. unknown.  jerovicii pneumon.& toxoplasmos., avoid lamivudine & concom. IV   rash, nerv.syst.& psych. sympts. report., be alert to psychos.-like
   Prevent.of mother.-foet.transmiss: Pregn. women over 14   ganciclovir, mitochondr.dysfunct., intermitt. ther.may incr.sensitisat.  reacts.& sev.ac.depress. incl.suicid.ideat./attempts.report., ment.
   wks.gestat.: 500 mg/day oral. (100 mg 5xdly.) until begin.of labour.   risk, eval. inflamm.sympt. & init.treatm.if need., alert dr.if joint pain   illn./subst. abuse hist., chron. liv.dis., monit.liv.enzymes partic. in
   Dur.labour & deliv.IV admin.2 mg/kg bm.over 1 hr.follow.by contin.   & stiffn./movem.diffic., ther.not a cure, opportunist.infects.& other   known/suspect. hepatit.B/C infect.hist./concom.hepatotox meds.,
   infus.of 1 mg/kg/hr.until umbilic.cord clamp.  HIV complicat.may still devel., inflamm.react.to asymptom./resid.   cholesterol./triglycerid.monit.
   Newborn infts.start.within 12hrs.aft.birth until 6 wks: 2 mg/kg   opportunist. infects.poss.if sev.immune defic.at time of ther.init.,   Drug interactions: Incr.CNS eff.with alcoh./ psychoact.meds.,
   bm.oral.6 hrly. Infts.unable to receiv. oral.dos. admin.1,5 mg/kg   advis.pt.that antiretrovir.ther.will not prev.transmiss.through sex.  plasma conc.of other compds. that are CYP3A4 substrat.poss.decr.,
   bm.IV infus.over 30 mins. every 6 hrs.  cont./bld.contam. & appropr.precaut.to contin.  AUC & C trough of indinavir decr., incr.freq.of S/E with ritonavir, decr.
   Haematologic.toxic.: Dos.reduct./interrupt.poss. necess.if Hb   Drug interactions: High virolog.fail.rate/resist.at early stage when   saquinavir/clarithromycin. AUC & C max , reduc. AUC & C max with ri-
   lev.falls to betw.7,5 & 9 g/dl OR neutrophil count falls to betw.0,75   abacavir & lamuvidine combin. with tenofovir as once dly.regim., tri-  fampicin, potent.interact with OC’s, methadone plasma lev.decr.
          9
   x10 /L & 1,0 x10 /L          methoprim incr. lamivudine plasma lev., rifampicin/ phenobarbit. /   result.in opiate withdr.signs in HIV infect.IV drug users, decr.eff.
    9
   Combin.ther: Dos.adjustm.for either drug to follow guideline   phenytoin poss.decr.abacavir conc., abacavir AUC incr.by ethanol,   of carbamazepine & efavirenz, potent.for reduc.eff.of phenytoin/
   of indiv.drug.               poss.interact.with retinoid cmpds.but not stud., syst.methadone   efavirenz plasma lev., decr. atorvastatin/ pravastatin/simvastatin
   Contraindications: Abnorm.low neutrophil.cell counts (less than   clear. incr., lamivudine poss.inhib.zalcitabine intracell. phosphorylat.  plasma lev., expect.reduc.conc.with St John’s Wort.
   0,75x10  litre)/ Hb levels (less than 7,5 g/ decilitre), concom.stavu-  EDURANT, Janssen [P/S]
      9
   dine & ribavirin, safety dur.first trimest.pregn.not est., breast-feed.  Rilpivirine  EFLATEN, Mylan [P/S]
   Side effects: Anaem., neutropen., leucopen., thrombocytopen.,   Indications: HIV1 infect.in combinat.with other antiretrovir.in   Tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg, efa-
   pancytopen.with marrow hypoplas., GI disturbs., oral mucosa pig-  treatm.-naïve adult pts.  virenz 600 mg
   mentat., sev. hepatomegaly with steatos., rais.liv.enzym.& bilirub.,   (S4) TABS, 46/20.2.8/0793  Indications: HIV-1 infect.adults over 18 yrs.who have been
   pancreatit., potent.fatal lact.acidos.in absence of hypoxia, myalg.,   720029-001: 25 mg, 30, R64,85  treat.& stabil.on a combinat.of the above separate formulat.at
   myopathy, asthen., anx., depress., nail & skin pigmentat., skin re-  Dosage: Always to be given in combinat.with other antiretrov.  simil.dosages.
   acts., sweat., dyspn., cough, chest/gen.pain, headache, dizzin., CNS   meds.,  (S4) TABS, 45/20.2.8/0171
   effs., pareasthes., psych.disords., convuls., urin.freq., gynaecomast.,   Adults: Recomm.dos: 25 mg once dly.with a meal.  718733-001: 30, R302,36
   taste pervers., fev., malaise, chills, flu-like syndr.  Miss.dos: If within 12 hrs.take ASAP & next dos.at sched.time.   Dosage: Ther. to be init. by physic.exper.in HIV managem. Adults:
   Special precautions: Concom.self-admin.meds., risk of trans-  If long.than 12 hrs.do not take miss.dos but resume with usual   1 tab.once dly.on empty stomach. Bedt. dos.may improve CNS
   miss.through sex.contact/bld. contamin. not reduc., inft.transmiss.  dos.sched.  sympt. tolerabil.
   still poss., not a cure, pts.at risk of develop.illn.assoc.with immune   Contraindications: Concom.NNRTI’s, concom. carbamazepine/ox-  Contraindications: Sev.ren./hepat.impairm., pregn. & lactat.,
   suppress.incl.opportunist.infects.& neoplasms/ other HIV infect.  carbazepine/phenobarb./phenytoin & dexamethas.except as sngl.  concom.astemizole/cisapride/ midazolam/ triazolam/pimozide/
   complicat., lymphoma develop. risk unknown, concom.phenytoin   dos.treatm., concom. rifabut./rifampic./rifapent./St John’s wort &   bepridil/ergot alkaloids/ St John’s wort, no data for dos.recomm. in
   bld.lev., monit. ren.funct./haematolog.paramet.& dos. reduct. if   PPI’s, safety in pregn.& lactat.not est., not recomm. in childr.& ado-  pts.over 65 yrs./pts.und.18 yrs., concom.meds. cont. tenofovir diso-
   reqd.with concom.nephrotox./ myelosuppress. meds., avoid con-  lesc.18 yrs or young.  proxil fumarate/lamivudine, lamivudine with concom.zalcitabine/
   com.ribavirin/ stavudine, admin.concom.prophylact.antimicrob. for   Side effects: Depress., insomn., headache, rash, abnorm.dreams,   IV ganciclov. or foscarnet, voriconazole, amprenavir/saquinavir not
   opportunist.infects., dos.in combinat.ther. should follow guideline of   naus.& dizzin., incr.transamin., decr.appetite, sleep disords., somnol.,   recomm., rare galactosaem.disords., gluc./ galact. malabsorpt.syndr.
   the indiv.drug, no studies in elderly &gt;65 yrs., monit.bef./dur.ther.in   abdom.pain & discomf., vomit., fatig, decr.Hb/platelet.& WBC count,   Side effects: Ren.impairm.incl. hypophosphataem., lactic.acidos.&
   elderly, imp.ren./hepat.funct., incr.neutropen. incid. with pre-exist.  baseline total-/LDL-/HDL-cholester & triglycer.changes  sev. hepatomegaly with steatos.incl.atal.with maj.of cases being
   neutropen./anaem./low vit.B 12 lev. & concom.paracet., incl.Hb.lev./  Special precautions: Not a cure theref.HIV transmiss.precaut.to   women, pancreatit., lipodystrophy, osteonecros., skin reacts.incl.
   neutrophil counts, suspend in case of any findings suggest. of lact.   be cont., baseline vir.load &gt;100 000 HIV-1 RNA exper.great.risk of   rash/erythema multiforme/ Stev.-John.syndr., ser.psych.sympts. incl.
   acidos./hepatotoxic., hepatomegaly/hepatit., known risk fact.for liv.  virolog. fail.& then high.rate of treatm.emerg.NNRTI class resist.,   sev. depress./suicid./delus.& pyschos.-like behav., CNS effs., dizzin.,
   dis., longt.effs.of in utero/ inft.expos.unknown.  pts.exper.virologic.fail.develop.lamivud./ emtricitabine assoc.re-  seiz., dyspn., GI disturbs., hepatit., incr.transaminas., myopathy, os-
   Drug interactions: Metabol.inhibit.by meds. prim. elimin.by hepat.  sist., co-admin.with meds. with known.risk of Torsade de pointes,   teomalac., ren./hepat.fail., Fanconi syndr., nephrit., nephrogen.diab.
   metabol., poss.tox.phenytoin lev., poss.alt.metabol.with aspir/co-  mechan.& long term conseq.of fat distribut.observ.curr. unknown,   insipid., asthen., hypertriglyceridaem., hypercholesterolaem., insul.
   deine/ morphine/ indomethacin/ketoprofen/naproxen/ oxazepam/   in sev.immune defic.at init.of combin. antiretrovir.ther. an inflamm.  resist., hyperglycaem., hyperlactataem., inflamm. react. to asympto-
   lorazepam/cimetidine/clofibrate/ dapsone/ isoprinosine esp.dur.  react.to asymptom./ residual opportun.infects.poss., admin. H2-  mat./resid.infects.in sev.immune defic. when init.ther., neutropen.,
   chron.combin.ther., incr. toxic.risk with concom.potent.nephrotox./   recept. antagon.12 hrs.bef./4 hrs.aft., admin.antacids 2 hrs.bef./4   anaem., thrombocytopen., pure red cell aplas., paraesthes., cough,
   myelosuppress. meds., antagonist.react.betw. concom. ribavirin/  hrs.aft., monit.methadone maint.ther., adeq.contracept.recomm.,   nas.sympt., alopec., arthralg., musc. disords., rhabdomyolys., fatig.,
   stavudine, poss.incr.AUC with probenecid & reduc.ren.excret., ri-  breast feed.not recomm., not stud.in sev.hepat.impairm., lact.intol.  malaise, fev., hypersens., somnol., abnorm.co-ordinat., blurr.vis.,
   fampicin poss. decr. AUC, mod.C max incr.with lamivudine.  Drug interactions: Clear.poss.affect.by meds. induc./ inhibit.   vertigo, gynaecomast.
                                                              Special precautions: Mod.to sev.ren.impairm., lamivudine/
   DUMIVA, Mylan [P/S]          CYP3A, poss.loss of therapeut. eff. with carbamazepine/oxcarbaz-  efavirenz excret.in breast milk, barr. contracept.in addit.to OC’s
   Abacavir sulph. 600 mg, lamivudine 300 mg  epine/phenobarb./ phenytoin/rifabut./rifampic./rifapentine /dexa-  recomm., women of childbear. potent.should undergo pregn.test.
   Indications: Treatm.of HIV infect.adults & adolesc. over age   methasone/ PPI’s & St John’s Wort, macrol. antibiot.incr.plasma   bef. init.ther., discont.if find.suggest.lact.acidos./ hepatotoxic., liv.
   of 12 yrs.                   conc., H 2-recept.antagon.& antacids decr.plasma conc., metha-  dis.risk fact., opportunist.infects. & HIV complic.may cont., not prov.
   (S4) TABS, 46/20.2.8/0012    done plasma conc.decr.        to prev. transmiss. risk through sex.cont./bld.contamin. theref. ap-
   717977-001: 60, R708,24      EFAVIRENZ WINTHROP, Zentiva [P/S]  propr.precaut.to be contin., discont. ther. immed.if S&S suggest.of
   Dosage: Pts.to be stabilis. on indiv.meds.bef.being switch. over   Efavirenz  pancreatit.occur, poss. mitochondr.dysfunct.in HIV-neg.infts.expos.
   to Dumiva. As a fix.dos.tab.do not admin.to pts.weigh.less than   Indications: In combinat.with other antiretrovir. agents for HIV-1   in utero &/ post-natal.to nucleoside analog., immune reactiv. syndr.,
   40 kg. Adults & adolesc.over 12 yrs: 1 tab.once dly. Refer to in-  infect.adults, adolesc.& childr. weigh.40 kg and above.  incr.risk for sev.potent.fatal hepat. adverse effs.in chron.hepat.B/C
   div.prod.lit.when necess.    (S4) TABS, 46/20.2.8/0039     pts.treat.with combin. ther., refer also to relev. prod.info.with con-
   Contraindications: Abnorm.low neutrophil counts/ low Hb lev.,   717778-001: 600 mg, 30, R246,15  com.antivir.ther.for hepatit. B/C, alert dr.in case of joint stiffn./pain/
   sev.ren.impairm., concom. emtricitabine, safety in pregn.not est.,   Dosage: Admin.in combinat.with a protease inhibit.and / nucleo-  movem. diffic., discont. ther.in case of desquamat./blister./mucos.
   lactat., safety & effic.in signif. underly.liv.disords.not est., childr.,   side analog. Admin.on empty stomach pref.at bedt. Consid.bedt.dos.  involvem., fev., psych.disord./seiz.hist., monit. plasma lev.with con-
   no studies in pts.&gt;65 yrs., mod.to sev. hepat.impairm., concom.  dur.1  2-4 wks ther.& in pts.exper. neurologic.effs.  com.phenytoin /carbamazepine/ phenobarb., consid. discont.other
                                   st
   zalcitabine not recomm.      Adults: Recomm.dos.: 600 mg once dly. Adolesc. & childr.(17   antiretrovir.to avoid drug resist. virus develop.if efavirenz discont.,
   Side effects: Lipodystrophy, hypersens.reacts. somet.fatal present.  yrs.& und): 600 mg at bedt. Use only in adults & childr.weigh.  eval.any inflamm.sympt., meas. fast.ser.lipids/bld.gluc., lipid dis-
   with fev.&/rash as part of syndr., N&V, diarrh., abd.pain, mouth ulc.,   great.than or equal to 40 kg.  ord.managem., avoid.concom.lamivudine with co-trimoxazole dos.
   dyspn., cough, sore throat, adult resp.distress syndr., resp. fail., fev.,   Contraindications: Concom.astemizole /cisapride /midazolam/   for PCP & toxoplasmos., efavirenz with lopinavir/ritonavir, monit.
   lethargy, malaise, oed., lymphadenopathy, hypotens., conjunctivit.,   triazolam/ergot derivat./ carbamazepine, pregn., safety in lactat.   cholester.lev.with concom. atorvastatin/pravastatin/simvastatin &
   anaphylax., lymphopen., elev.LFT, hepatit., hepat./ ren. fail., myalg.,   not est., childr.less than 3 yrs./weigh.&lt;13 kg, concom.St John’s   efavirenz, monit.for withdr.sympt.with methadone, teratogenic.in
   myolys., arthralg., immune reactiv. syndr., osteonecros., hypertriglyc-  Wort, galact.intol.hist., Lapp lact.defic., gluc-galact.malabsorpt.  animals, monit.hepat.funct.for sev.mnths.in pts.co-infect.with HIV
   eridaem., hypercholesterolaem., insul.resist., hyperglycaem., hyper-  Side effects: Ser.psych./CNS effs., allerg.reacts., anorex., redis-  & HBV who discont.ther., not indic.for HBV infect., init.anti-hepatit.B
   lactataem., bld.dyscras., headache, periph. neuropathy, nas.sympt.,   tribut./ accumulat.of body fat, alcoh. intol., incr.appet., weight gain/  ther.if appropr., avoid with concom./ rec.nephrotox. agents, monit.
   pancreatit., GI disturbs., rash, alopec., erythem.multiforme, Stev.  loss, psych.disords. incl. delusion/ psychos./suic.ideat./attempts,   ren.funct.bef.init.& reg.theraft., avoid in antiretrovir.exper.pts.with
   John. syndr., tox.epiderm.necrolys., musc.disords., rhabdomyolys.  CNS effs., dizzin., headache, hypoaesthes., anx., convuls., periph.  strains harbour.K65R mutat., cons.interrupt./ discont. ther. if evid.
   Special precautions: Reproduct.toxic.in animals, excret.in breast   neuropathy, migraine, neuralg., paraesthes., tremor, abnorm.vis., tin-  of worsen.liv.dis., concom. didanosine not recomm., do not admin.
   milk, HLA-B*5701 allele screen. advis. bef.ther.init., discont.ther.in   nit., vertigo, syncope, palpitat., tachycard., asthma, URTI, dyspn., GI   concom. saquinavir as sole protease inhibit., cons.altern. antifung.
   pts.develop. hypersens. & not re-challenge, sympt.return which   disturbs., abd.pain, abnorm.co-ordinat., malabsorpt., hepatit., hepat.  treatm.to itraconazole, obesity & prolong. nucleoside use poss. risk
   more sev. incl.life-threat.hypotens./death when restart. ther. aft.  fail., skin reacts., incr.sweat., alopec., erythema multiforme & Stev.-  fact.for lact.acidos.
   hypersens.reacts., pts.to be aware of dangers of hypersens., use   Johns.syndr., nail disords., arthralg./myalg., myopathy, impot., libido   Drug interactions: Incr.tenofovir AUC with lopinavir/ritonavir,
   facil.where medic. assist. avail.if ther.restart, lact.acidos./sev. he-  chang., flush., fatig., asthen., malaise, hot flush., flu-like sympts., rais.   incr.zidovudine expos.with tenofovir, incr lamivudine expos.with
   patomegaly with steatos.incl.fatalit.with lamivudine, alone or in   ser. cholester. & triglycerid.conc., rais.liv.enzym.  concom. trimethoprim, lamivudine poss.inhib.zalcitabine intracell.
   combin., discont.ther.in case of rais.lactat. lev., obese women with   Special precautions: Must not be used as monother. / add.on   phosphorylat., reduc.atorvastat/ pravastin/ simvastin plasma conc.
   MI/ hepatomegaly/ hepatit./any liv.dis.risk fact./ hepat. steatos.,   as sole agent to fail.regim., vir.cross-resist.potent.if new concom.  with concom. efavirenz, decr. methadone lev./opiate withdr. signs
   pts.co-infect.with hepatit.C & treat. with alpha interfer.& ribavirin,   anti-retrovir. agents used, liv.enzym. monit.with ritonavir, concom.   with efavirenz, efavirenz reduc.plasma lev. with St John’s wort, incr.
   MI risk fact., eval. physic. signs of fat redistribut., meas.fast.ser. li-  saquinavir as sole protease inhibit.not recomm., consid.alternat.to   didanosine adverse eff. risk with tenofovir., plasma conc.of other
   pids/ bld.gluc., lipid disords.managem., init.ther. by physic.exper.in   clarithromycin, incr. dos.with concom.rifampicin, use barrier contra-  compds. that are CYP3A4 substrat.poss.decr., incr. clinic. adverse</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page304.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>
             </td>
             <td width="35%"><a href="page306.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page306.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
